# Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

> **NCT03007732** · PHASE2 · COMPLETED · sponsor: **David Oh** · enrollment: 23 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** SD-101
- **DRUG:** Leuprolide acetate
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT03007732
- **Lead sponsor:** David Oh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-17
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03007732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03007732, "Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03007732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*